JB Pharma acquires cardiac brand from Glenmark for Rs 314 crore

JB Pharma on Wednesday said it has acquired cardiac brand Razel (rosuvastatin) for India and Nepal region from Glenmark for Rs 314 crore in an all-cash deal. The acquisition will be funded through long-term debt and internal accruals, the KKR-backed company said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news